Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge

Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge

The use of immune-checkpoint inhibitor (ICI) therapy has significantly improved patient outcomes in a wide variety of cancers and has become a cornerstone in the treatment of renal cell carcinoma. However, ICI treatment has the potential to cause a variety of immune-related adverse events (irAEs) th...

Full description

Bibliographic Details
Main Authors: Matthew Scarlotta, Robin Avery, Ezra Baraban, Zahra Maleki, Yasser Ged
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
lymphadenopathy
renal cell carcinoma
diffuse large B-cell lymphoma
sarcoid-like reaction
histoplasmosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.876797/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.876797/full

Similar Items